币界网报道：Synaptogenix has rebranded as TAO Synergies following a $10 million investment in TAO tokens, signaling a strategic shift towards blockchain and AI integration. The company, previously focused on neurodegenerative disease research, will now pivot to developing decentralized AI solutions. CEO Alan Tuchman stated the rebrand reflects their commitment to "harnessing blockchain's potential to revolutionize AI development." The funding will support research into neural network optimization using distributed ledger technology. TAO Synergies plans to launch its first AI protocol on Ethereum later this year, aiming to create open-source tools for machine learning model training. The move comes as increasing numbers of biotech firms explore Web3 applications, with several recently announcing similar transitions into blockchain-based AI development. Industry analysts note this reflects growing institutional interest in tokenized research initiatives.